A detailed history of Principal Financial Group Inc transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 25,775 shares of RLAY stock, worth $163,929. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,775
Previous 27,655 6.8%
Holding current value
$163,929
Previous $304,000 29.93%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$7.5 - $12.07 $14,100 - $22,691
-1,880 Reduced 6.8%
25,775 $213,000
Q4 2023

Feb 07, 2024

SELL
$6.01 - $11.48 $16,882 - $32,247
-2,809 Reduced 9.22%
27,655 $304,000
Q3 2023

Nov 02, 2023

BUY
$8.24 - $12.97 $37,137 - $58,455
4,507 Added 17.36%
30,464 $256,000
Q2 2023

Aug 07, 2023

SELL
$9.99 - $18.27 $7,502 - $13,720
-751 Reduced 2.81%
25,957 $326,000
Q1 2023

May 09, 2023

BUY
$15.0 - $22.76 $45,300 - $68,735
3,020 Added 12.75%
26,708 $439,000
Q4 2022

Feb 09, 2023

BUY
$14.16 - $24.02 $43,046 - $73,020
3,040 Added 14.72%
23,688 $353,000
Q3 2022

Nov 09, 2022

BUY
$18.07 - $31.37 $70,454 - $122,311
3,899 Added 23.28%
20,648 $462,000
Q2 2022

Aug 10, 2022

SELL
$13.31 - $34.88 $76,173 - $199,618
-5,723 Reduced 25.47%
16,749 $280,000
Q1 2022

May 09, 2022

BUY
$20.26 - $32.36 $1,458 - $2,329
72 Added 0.32%
22,472 $673,000
Q4 2021

Feb 09, 2022

SELL
$26.0 - $37.03 $202,176 - $287,945
-7,776 Reduced 25.77%
22,400 $688,000
Q3 2021

Nov 09, 2021

BUY
$29.75 - $37.99 $9,698 - $12,384
326 Added 1.09%
30,176 $952,000
Q2 2021

Aug 10, 2021

BUY
$27.5 - $38.19 $581,542 - $807,603
21,147 Added 242.99%
29,850 $1.09 Million
Q1 2021

May 10, 2021

BUY
$32.52 - $61.53 $60,227 - $113,953
1,852 Added 27.03%
8,703 $301,000
Q4 2020

Feb 08, 2021

BUY
$35.51 - $54.03 $243,279 - $370,159
6,851 New
6,851 $285,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $765M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.